Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Acquisitions & Divestments (2021 - 2025)

Historic Change in Acquisitions & Divestments for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $70.0 million.

  • Aligos Therapeutics' Change in Acquisitions & Divestments rose 13333.33% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.0 million, marking a year-over-year increase of 9996.0%. This contributed to the annual value of $90.0 million for FY2024, which is 9995.11% up from last year.
  • Latest data reveals that Aligos Therapeutics reported Change in Acquisitions & Divestments of $70.0 million as of Q3 2025, which was up 13333.33% from $20.0 million recorded in Q1 2025.
  • Over the past 5 years, Aligos Therapeutics' Change in Acquisitions & Divestments peaked at $70.0 million during Q3 2025, and registered a low of $11000.0 during Q3 2023.
  • For the 5-year period, Aligos Therapeutics' Change in Acquisitions & Divestments averaged around $23.5 million, with its median value being $20.0 million (2023).
  • As far as peak fluctuations go, Aligos Therapeutics' Change in Acquisitions & Divestments crashed by 9997.06% in 2023, and later surged by 27262727.27% in 2024.
  • Aligos Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $10.0 million in 2021, then surged by 262.2% to $36.2 million in 2022, then plummeted by 99.97% to $11000.0 in 2023, then surged by 181718.18% to $20.0 million in 2024, then soared by 250.0% to $70.0 million in 2025.
  • Its last three reported values are $70.0 million in Q3 2025, $20.0 million for Q1 2025, and $20.0 million during Q4 2024.